Publications

2021

Nam G, Singh K, Lopresti ML, Ouseph MM, Wang LJ, Wang Y. How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study. Technol Cancer Res Treat. 2021;20:15330338211035037.
Linares JF, Zhang X, Martinez-Ordoñez A, Duran A, Kinoshita H, Kasashima H, et al. PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. Mol Cell. 2021.
Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, et al. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021;5.
Vertesich K, Sosa BR, Niu Y, Ji G, Suhardi V, Turajane K, et al. Alendronate enhances osseointegration in a murine implant model. J Orthop Res. 2021;39(4):719-726.
Hissong E, Yantiss RK. The Frontiers of Appendiceal Controversies: Mucinous Neoplasms and Pseudomyxoma Peritonei. Am J Surg Pathol. 2021;Publish Ahead of Print.
Miltiadous O, Petrova-Drus K, Kaicker S, Mathew S, Kluk M, Geyer JT, et al. Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm. Blood Adv. 2021.
Tang X-, Melis M, Lu C, Rappa A, Zhang T, Jessurun J, et al. A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease. J Biol Chem. 2021;297(6):101331.
Méndez-Solís O, Bendjennat M, Naipauer J, Theodoridis PR, Ho JJ, Verdun RE, et al. Kaposi's sarcoma herpesvirus activates the hypoxia response to usurp HIF2α-dependent translation initiation for replication and oncogenesis. Cell Rep. 2021;37(13):110144.
McIntire PJ, Elsoukkary SS, Robinson BD, Siddiqui MT. High-grade urothelial carcinoma in urine cytology: different spaces - different faces, highlighting morphologic variance. J Am Soc Cytopathol. 2021;10(1):36-40.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700